The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.
Request a Letter of Authorization (LOA) from the pharmaceutical company that makes the investigational drug you wish to obtain. A LOA grants the right of reference to the information contained in the supplier’s existing Investigational New Drug (IND) application. If a LOA is not available, submit sufficient information for FDA to assure the product’s quality. A Letter of Authorization template is available from FDA.
Submit Form FDA 3926
Instructions for filling out Form FDA 3926 are available online.
Submit Form FDA 3926 (along with the LOA) to FDA. You may submit via mail, fax, or e-mail. Further instructions and help about how to submit available online.
Obtain IRB approval
Obtain IRB approval per 21 CFR Part 56. A physician submitting an individual patient expanded access IND using Form FDA 3926 may choose to request authorization to obtain concurrence by the IRB chairperson or by a designated IRB member before the treatment use begins, in lieu of obtaining IRB review and approval at a convened IRB meeting at which a majority of the members are present. A physician submitting an individual patient expanded access IND using Form FDA 1571 may include a separate waiver request with the application.
Obtain Informed Consent
Obtain Informed Consent from patient or their legally authorized representative per 21 CFR Part 50.
Report unexpected fatal or life-threatening suspected adverse reactions to FDA as soon as possible but in no case later than 7 calendar daysafter the sponsor’s initial receipt of the information.
Report serious and unexpected suspected adverse reactions to FDA as soon as possible but in no case later than 15 calendar daysafter determining that the information qualifies for reporting.
See 21 CFR 312.32 for further information on mandatory safety reporting.
Amendments
Any time
Submit protocol and information amendments to FDA for any changes to the initial Expanded Access IND submission per 21 CFR Part 312 (312.30 and 312.31).
Summary
Following completion of treatment
When treatment is complete, submit a summary of expanded access use per 21 CFR 312.310(c)(2).
Annual Report
Within 60 days of the anniversary date
Submit an annual report within 60 days of the anniversary date that the Expanded Access IND went into effect per 21 CFR 312.33.
The Annual Report is not required if treatment was completed and FDA was notified before one year passed.